Navigation Links
Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
Date:1/10/2008

STRASBOURG, France, January 10 /PRNewswire-FirstCall/ -- Transgene (Euronext Paris: FR0005175080) announces promising preliminary data from the Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

This on-going trial is a randomized, open label and controlled study designed to assess the efficacy of TG4010 in combination with cisplatin and gemcitabine compared to the chemotherapy regimen alone. The trial completed the enrolment of 148 patients at the end of May 2007 and was conducted in 27 centres located in France, Poland, Germany, and Hungary. The patients had NSCLC expressing MUC1, either stage IIIB with effusion or stage IV, and had not received prior systemic treatment for their advanced disease. Half of the patients received the combination regimen (TG 4010 vaccine plus chemotherapy) and the other half of the patients received chemotherapy alone.

The trial confirmed the favourable safety profile of TG4010 when associated to chemotherapy: most adverse events observed so far were considered related to chemotherapy as well as to the underlying disease. Hematological toxicity was equivalent in both treatment groups. Most frequent adverse events related to TG4010 were injection site reactions and asthenia, which are classical vaccine associated reactions.

Based on the local evaluations performed at investigation centres, results so far are showing a positive trend in favour of the combination of TG4010 with the chemotherapy. These results nevertheless remain subject to a centralised review process that is presently on-going.

"We report today encouraging trends on the preliminary results of our Phase IIb trial with TG4010 in non-small cell lung cancer" said Philippe Archinard, Chief Executive Officer of Transgene. "We expect to present data during the second quarter of this year and final data by the fourth qua
'/>"/>

SOURCE Transgene S.A.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
2. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
3. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
4. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
5. MultiCell Technologies To Increase Focus on Therapeutic Candidates
6. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
7. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
8. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
9. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
10. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
11. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced that ... at two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ... Second Annual Marcum LLP Microcap Conference on Thursday, May ... York City.  The presentation is scheduled to begin at ...
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
(Date:5/23/2013)... African Ancestry , Inc., the ... African descent, today announced new product enhancements to ... all races, myDNAmix determines various ancestries included in ... Americas (Native American), East Asia, West Sub-Saharan Africa, ... Originally launched in late 2011, the enhanced product ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Bed bugs ... the university had already confirmed it. Meanwhile, My Cleaning Products ... bed bug victims fight the pests without using harmful chemical ... on May 15, 2013, the affected building was actually a ... being infested was said made on May 13 and bed ...
Breaking Biology Technology:Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... to Drink,Suite of Nutritional Supplements to Provider Services, Inc. to be ... ... 5 Millennium Biotechnologies,Inc., wholly owned subsidiary of Millennium Biotechnologies Group, ... an,amendment of it,s November 9th 2007 Master Purchase Contract with Provider,Services, ...
... for Growth in 2009 and ... ... Monsanto,s international,seed brands serve as an ideal launching pad that positions ... ramp-up,speed, Brett Begemann, Monsanto,s executive vice president of global,commercial, will tell ...
... for Mass Spectrometry ... Denver, June 2-5, 2008-, EMERYVILLE, Calif., June 5 ... it has developed a novel analytical,2-dimensional liquid chromatography mass ... sensitive,automated quantification of the active pharmaceutical compounds of MF101,the ...
Cached Biology Technology:Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 2Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 3Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 2Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 3Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 4Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 2Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 3
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
(Date:5/22/2013)... details on how climate change will affect interactions between ... Journal of Animal Ecology . This knowledge, they ... policymakers of how species are likely to be impacted ... growing recognition among biologists that climate change is affecting ... is going to have very important consequences for the ...
(Date:5/22/2013)... the biodiversity of pollinating insects and wild plants have ... , Researchers led by the University of Leeds and ... evidence of dramatic reductions in the diversity of species ... and 1980s. , But the picture brightened markedly after ... losses among bees, hoverflies and wild plants. ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... tissue as well as eradicating the tumour it is ... often causing nasty side effects. A new development ... accurate treatment for cancerous tumours by using real-time images ... combining radiation treatment with non-invasive MR imaging, would be ...
... release is available in French . ... the chilli cook-off, usually has a key secret ingredient, ... crucial proteins, which change the dynamics of cells from ... involving McGill University, the Research Institute of the McGill ...
... . , Montreal, May 19th 2009 - Cocaine ... its abuse has become widespread since the end of the ... about its effects on the human brain or the mechanisms ... Marco Leyton, of the Montreal Neurological Institute (MNI), McGill University ...
Cached Biology News:Proteomics: Finding the key ingredients of disease 2Cocaine: Perceived as a reward by the brain? 2
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Biology Products: